We are revolutionizing neonatal intensive care with NEOLA®, a medical device that can offer continuous lung monitoring of preterm born infants and real-time alerts of life-threatening complications to provide better care and improve quality of life.
A word from our CEO Hanna Sjöström
Our mission is to give preterm born infants a better start in life. By providing neonatal intensive care units (NICUs) with a groundbreaking innovation for continuous lung monitoring that also can provide immediately alert to the personnel of serious health complications, we are upgrading the care that these fragile patients currently receive and filling a unique market gap for pediatric medical devices.
CEO, GPX Medical AB
Addressing a critical medical need
Every year almost 15 million children are born preterm (before 37 weeks of pregnancy). Many of them require intensive care. Many people know someone who was born preterm or has been affected by a preterm birth, but fewer understand the risks that arise from it. One of many challenges preterm born infants face is underdeveloped lungs that are unable to provide oxygen to the blood, resulting in a life-threatening condition that, if survived, can lead to complications later on in life.
GPX Medical’s technological innovation NEOLA® can help healthcare personnel make more informed decisions based on real-time information. GPX Medical’s proven technology uses laser spectroscopy to continuously measure lung volume changes and oxygen gas concentration in preterm infants. This is a safe and non-invasive method to monitor the lungs of these vulnerable patients in real time, thereby provide the possibility of instant treatment of life-threatening conditions and decreasing the risk of disabilities later in life.
NEOLA® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants.
Building on a historic Swedish legacy of medical technology innovation
Sweden has made invaluable contributions to global healthcare, specifically in neonatal intensive care. As a result, the survival rate of preterm born infants has increased to almost 90 percent. Such was not the case in the 1970s, when modern neonatal care was first introduced. At that time, the mortality rate of children weighing under one kilo was over 90 percent. Since then, Sweden has helped develop world class neonatal intensive care, built on a foundation of the latest technology and nurturing methods that involve parents as well.
Following in the footsteps of diagnostic ultrasound, which was developed in Lund, Sweden in the 1950’s, Lund-based medical technology innovation once again has the potential to revolutionize health care the world over.
GPX Medical Headquarters
Founded in 2016 and headquartered in Lund, Sweden, GPX Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. GPX Medical’s employees, management and board have a wide-ranging, specific and very competitive knowledge of product development, user needs and commercialization of medical technology, making the company well-positioned to take NEOLA® to market.
Märta Lewander Xu
Chariman GPX Medical
CEO Gasporox AB
Chairman Gasporox AB
CEO Norsk Elektro Optikk AS
Professor of Oncology Lund University Hospital
CTO CLS AB
CTO, member of board,
BiBB Instrument AB
We are on a journey to revolutionize neonatal intensive care
Learn more about investing in GPX Medical